Analysis of the main functions and clinical therapeutic effects of odexibat (Belvi)

1. Drug Overview and Mechanism of Action

Odevixibat (Odevixibat) is an oral selective bile acid transporter inhibitor (IBAT inhibitor), mainly used to treat progressive familial cholestatic liver disease (PFIC, Progressive Familial Intrahepatic Cholestasis). PFICIt is a rare hereditary liver disease. Patients usually suffer from bile acid accumulation in liver cells due to bile excretion disorder, which leads to severe itching, liver damage and abnormal liver function.

Odesibat selectively inhibits the bile acid transporter (IBAT/ASBT) in the terminal small intestine, thereby reducing the return of bile acids into the liver, thereby reducing blood and liver bile acid levels. The core advantage of the drug is that it is highly targeted, can be taken orally, and its mechanism of action directly interferes with the bile acid cycle, thereby relieving itching symptoms and delaying the progression of liver damage.

2. Main efficacy and clinical indications

The main effects of odexibat are reflected in Improvement of itching symptoms, reduction of serum bile acid levels and improvement of liver function indicators. Its indications include:

1.PFICPatients: especially children with severe itching, elevated bile acids and abnormal liver function;

2.Other cholestasis-related diseases: such as adjuvant treatment of cholestasis or biliary liver disease, but the main data are still based on PFIC.

Clinical studies have shown that odexibat can significantly relieve itching symptoms, improve patients' sleep quality and quality of life, and at the same time reduce liver cell damage by reducing serum total bile acid (sTBA) levels, thereby delaying disease progression.

3. Analysis of clinical treatment effects

Odesibat has shown significant efficacy in multiple clinical trials. Phase I and II studies have shown that PFICin pediatric patients after taking odexibat for weeks to months:

1. The symptoms of itching were significantly relieved, the itching score dropped significantly, and the number of scratches at night was reduced;

2. Serum bile acid levels are reduced, and some patients can return to close to the normal range;

3.Liver function indicators have improved, and ALT, AST and bilirubin levels have decreased;

4.The quality of life has improved. Children and parents reported that the patient's sleep has improved, behavioral anxiety has decreased, and the ability to perform daily activities has increased.

In addition, long-term use of odexibat shows good tolerance Most adverse reactions are mild to moderate, including diarrhea, abdominal pain and mild gastrointestinal discomfort, which can be alleviated through dose adjustment or symptomatic treatment.

4. Clinical application suggestions and future prospects

The clinical application of odexibat should follow the guidance of professional physicians and the principle of individualized dose adjustment . Suggestion:

1.ChildrenPFICFor patients, the initial dose should be set based on weight and bile acid levels, and hematology and liver function indicators should be monitored regularly;

2.Side effects management, mild diarrhea or gastrointestinal discomfort can be alleviated by adjusting the dose or medication time to avoid voluntary discontinuation of medication;

3. Long-term efficacy follow-up, regular assessment of pruritus scores, bile acid levels and liver function, combined with other drugs or surgical intervention, such as biliary shunt or liver transplantation, if necessary;

4. Potentially expanded indications, the value of use can be explored in other cholestasis-related diseases in the future, and non-surgical treatment options can be provided for more patients.

In summary, odexibat can effectively alleviate the itching symptoms of PFIC patients and improve liver function and quality of life by inhibiting intestinal bile acid recycling and reducing blood bile acid levels. Its good tolerability and clear mechanism of action make it an innovative treatment option for rare cholestatic liver diseases, while providing a scientific basis for future drug development for bile-related diseases.

Reference link:https://www.drugs.com